inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. oxygen saturation by pulse oximeter ≥92% on room air 6. negative urine or serum pregnancy test (if woman of childbearing potential). 7. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 8. ability to complete the daily diary independently. 9. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. oxygen saturation by pulse oximeter ≥92% on room air 6. negative urine or serum pregnancy test (if woman of childbearing potential). 7. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 8. ability to complete the daily diary independently. 9. the patient must give informed consent

inclusion criteria: patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. males and females ≥age 18 years. oxygen saturation by pulse oximeter ≥92% on room air negative urine or serum pregnancy test (if woman of childbearing potential). females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. ability to complete the daily diary independently. the patient must give informed consent

inclusion criteria: patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. males and females ≥age 18 years. oxygen saturation by pulse oximeter ≥92% on room air negative urine or serum pregnancy test (if woman of childbearing potential). females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. ability to complete the daily diary independently. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. oxygen saturation by pulse oximeter ≥92% on room air 6. negative urine or serum pregnancy test (if woman of childbearing potential). 7. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 8. ability to complete the daily diary independently. 9. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr or antigen assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr or antigen assay within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. oxygen saturation by pulse oximeter ≥92% on room air 6. negative urine or serum pregnancy test (if woman of childbearing potential). 7. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 8. ability to complete the daily diary independently. 9. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥92% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 5 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥92% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 3 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥92% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 3 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥92% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 3 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥88% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent

inclusion criteria: 1. patients with symptomatic, diagnostically confirmed covid-19, per rt-pcr assay of respiratory tract sample. 2. patient must have either become symptomatic or found positive by rt-pcr within 3 days, whichever is greater, of randomization. 3. patients must fill out a baseline questionnaire which is reviewed by study personnel to determine eligibility. 4. males and females ≥age 18 years. 5. at baseline the laboratory parameters listed below are not worse than nci ctcae v5.0 grade 2, with exceptions noted below: - bilirubin ≤ 1.5 times upper limit of normal (uln; grade 1 only) - ast (sgot), alt (sgpt) ≤ 5.0 x uln, - serum creatinine ≤ 1.5 x uln (grade 1) - albumin ≥ 2.0 g/dl 6. acceptable hematologic status: - absolute neutrophil count ≥1000 cells/mm3 - platelet count ≥50,000 plt/mm3 - hemoglobin ≥ 8.0 g/dl 7. clinically acceptable blood sugar control in the opinion of the investigator. 8. inr and partial thromboplastin time (ptt) each ≤ 1.5 x uln (i.e., grade 1), unless patient is taking dabigatran or heparin. 9. oxygen saturation by pulse oximeter ≥88% on room air 10. negative pregnancy test (if woman of childbearing potential). 11. females of childbearing potential and males with female partners of childbearing potential must agree to use acceptable contraceptive methods during the study and for at least two months after the last dose of study medication. 12. ability to complete the daily diary independently. 13. the patient must give informed consent